Deal Round-up 20/06/01

Hg invests in Acuid, Aberdeen’s White Rose backs medical research

Hg invests in Acuid

HgCapital, the European private equity firm formerly known as Mercury Private Equity, this week invested $8m in Acuid, a company developing semiconductors for memory management in computer processors.

Based in the UK, Acuid says its products significantly increase the speed and accuracy of electronic systems. Its technology has applications in high speed system design, digital interfaces, communications, ATE and automation.

Aberdeen’s White Rose backs medical research

The White Rose Technology Seedcorn Fund (“WRTSF”) has invested £250,000 to fund research into the treatment and diagnosis of prostate and cervical cancer.

Advised by Aberdeen Murray Johnstone Private Equity, the WRTSF is backing the establishment of Pro-Cure Therapeutics Limited (“Pro-Cure”), a new company that has been set up to own and develop the Intellectual Property arising from the research by Professor Norman Maitland and his team at the University of York.

Professor Maitland specialises in carrying out research into the use of therapeutic viruses to treat prostate cancer, increasingly sensitive and accurate testing methods for cervical cancer, as well as other related areas.